Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620223 | 1.00 | MAPT (0.36) | MAPTHPGDL3MBTL1KMT2AMEN1 | |
| SCHEMBL27419578 | 0.99 | MAPT (0.36) | MAPTHPGDL3MBTL1KMT2AMEN1 | |
| SCHEMBL8618608 | 0.89 | BTN3A1 (0.37) | KMT2AMEN1 | |
| SCHEMBL8623000 | 0.87 | KMT2A (0.43) | MAPTKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL8618472 | 0.87 | S1PR1 (0.40) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL8623006 | 0.87 | KMT2A (0.43) | MAPTKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL8618467 | 0.87 | S1PR1 (0.40) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL8618638 | 0.82 | NPSR1 (0.40) | MAPTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL8618632 | 0.82 | NPSR1 (0.40) | MAPTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL8625187 | 0.80 | FDFT1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| CN-1089614-A | Alpha-phosphonosulfonate squalene synthetase inhibitors and method | SQUIBB & SONS INC (US) | 1994-07-20 | — | — | CN | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |